The 2012 and 2014 ballots approving legalization of cannabis in four U.S. states have stirred the pot, so to speak, on a wide range of issues and nuances related to the herb — not least marijuana’s clinical use as a therapeutic agent. Medical marijuana remains a topic of debate in the health sciences community, but currently the sale and possession of marijuana is legal for both medical and non-medical use in four states: Alaska, Colorado, Oregon, and Washington, and 23 U.S. states and the District of Columbia have legalized medical marijuana.
As a public health issue, there are many nuances related to the use of cannabis, whether medicinally or recreationally, including its effectiveness — or not — in treating the astonishing range of disorders, including Multiple Sclerosis (MS), for which it is claimed by advocates to be beneficial. However, current scientific research either pro or con cannot be regarded as conclusive if for no other reason than that there is so relatively little of it for a variety of reasons, particularly bureaucratic and judicial roadblocks to legal acquisition of marijuana for research purposes, which inhibits approval and funding of marijuana research.
NEMUS Bioscience Inc. is a biopharmaceutical startup that hopes to help bridge the cannabis clinical research gap. The company’s activities are primarily focused on research, development and commercialization of a diverse range of new medicines and other chemicals derived from cannabinoids, a class of chemical compounds extracted from the Cannabis Sativa herb of the Hemp family, one of which — tetrahydrocannabinol, or THC — is the psychoactive constituent in marijuana. In addition to Cannabis Sativa, there are more than 100 cannabinoids — some of which are believed to have powerful medicinal and therapeutic qualities.
NEMUS’s corporate vision is to offer physicians and patients “condition-specific” cannabinoid-based medicines designed to alleviate symptoms associated with a range of diseases, and to become a leading developer of cannabis-based therapeutics to address unmet medical needs on a global basis.
~~~~~~~~~~~~~~~~~~~~
.
.
.
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
